Polycystic ovary syndrome: A multidisciplinary challenge

Endocrinologist

Volumn 6, Issue 1, 1996, Pages 19-29

  Soulez, Benoît ^a   Dewailly, Didier ^a,c   Rosenfield, Robert L ^b  

^a UNIV LILLE   (France)

^b UNIVERSITY OF CHICAGO   (United States)

^c USN A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; CLOMIFENE CITRATE; CORTICOSTEROID; CYPROTERONE ACETATE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; TESTOSTERONE;

ANOVULATION; CLINICAL FEATURE; DYSLIPIDEMIA; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; INTRADERMAL DRUG ADMINISTRATION; MENSTRUATION DISORDER; OBESITY; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; REVIEW; WEIGHT REDUCTION;

EID: 0030032096     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199601000-00004     Document Type: Review

References (105)

1. Ehrmann DA, Barnes RB, Rosenfield RL: Hyperandrogenism, hirsutism, and the polycystic ovary syndrome. In Endocrinology, 3rd Ed., Vol. 3, edited by De Groot LJ, Besser M, Burger HG, et al., pp. 2093-112, Philadelphia, W.B. Saunders 1994.
2. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome: a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995 (in press).
3. Nobels F, Dewailly D: Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992; 58: 655-66.
4. Lucky AW, Rosenfield RL, McGuire J, Rudy S, Heike J: Adrenal androgen hyperresponsiveness to ACTH in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62: 840-5.
5. Ibanez I, Potau N, Virdis R, et al.: Postpubertal outcome in girls diagnosed of premature pubarche during chilhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1599-603.
6. Kiddy DS, Sharp PS, White DM, et al.: Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990, 32: 213-20.
7. Lobo RA, Goebelsmann U: Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am Obstet Gynecol 1980; 138: 720-6.
8. Yen SSC: The polycystic ovary syndrome. Clin Endocrinol 1980; 12: 177-208.
9. Lobo RA: The role of the adrenal in polycystic ovary syndrome. Semin Reprod Endocrinol 1984; 2: 251-62.
10. Nagamani M, Hannigan EV, Dinh TV, Stuart A: Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988; 67: 144-8.
11. Rebar R, Judd HL, Yen SCC, Rakoff J, Vandenberg G, Naftolin F: Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57: 1320-6.
12. Zumoff B, Freeman R, Compey S, Saenger P, Markowitz M, Kream J: A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic ovary syndrome. N Eng J Med 1983; 309: 1206-11.
13. Fauser BCJM, Pache TD, Hop WCJ, De Jong FH, Dahl KG: The significance of serum luteinizing hormone measurements in women with menstrual cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clin Endocrinol 1992; 37: 445-52.
14. Govan ADT, Black WP: Some observations on the histology of polycystic ovarian disease. In Functional Morphology of the Human Ovary, edited by Coutts JRT, pp. 37-52, Cambridge, MA, MTP Press Limited 1981.
15. Goldzieher MW, Green JA: The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962; 22: 325-38.
16. Hughesddon PE: Morphology and morphogenesis of the Stein-Leventhal ovary and so called hyperthecosis. Obstet Gynecol Surv 1982; 37: 59-77.
17. Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D: Polycystic ovarian disease: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertil Steril 1991; 55: 1062-8.
18. Dewailly D, Robert Y, Helin I, et al.: Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol 1994; 41: 557-62.
19. Rajaniemi HJ, Ronnberg L, Kauppila A, Yiostalo P, Vihko R: Luteinizing hormone receptors in ovarian follicles of patients with polycystic ovarian disease. J Clin Endocrinol Metab 1980; 51: 1054-7.
20. Barnes RB, Lobo RA: Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 1985, 61: 779-82.
21. Gumming DC, Reid RL, Quigley ME, Rebar RW, Yen SCC: Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endocrinol 1984; 20: 643-8.
22. Melrose P, Gross L: Steroid effects on the secretory modalities of gonadotropin-releasing hormone release. Endocrinology 1987; 121: 190-9.
23. Kalra PS, Kalra SP: Discriminative effects of testosterone on hypothalamic luteinizing hormone-releasing hormone levels and luteinizing hormone secretion in castrated male rats: analyses of dose and duration characteristics. Endocrinology 1982, 111: 24-9.
24. Yen SSC, Laughlin GA, Morales AJ: Interface between extra- and intraovarian factors in polycystic ovarian syndrome. Ann NY Acad Sci 1993; 687: 98-111.
25. Blankenstein J, Rabinovici J, Goldenberg M: Changing pituitary reactivity to follicle stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987, 65: 1164-7.
26. Chang RJ, Laufer LR, Meldrun DR, Nakamura RM, Judd HL, Kaplan SA: Steroid secretion in polycystic ovary disease after ovarian suppression by a long acting gonadotropin releasing hormone agonist. J Clin Endocrinol Metab 1983; 56: 897-903.
27. Rosenfield RL, Barnes RB, Cara JF, Lucky AW: Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome. Fertil Steril 1990; 53: 785-90.
28. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z: Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-62.
29. Escobar-Morreale H, Pazos F, Potau N, Garcias-Robles R, Sancho JM, Varela C: Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperandrogenism: role of adrenal and ovarian cytochrome P450c17α. Fertil Steril 1994; 62: 521-30.
30. Dewailly D, Vantyghem-Haudiquet MC, Sainsard C, et al.: Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J Clin Endocrinol Metab 1986; 63: 418-23.
31. Carmina E, Miles RA, Stanczyk FZ, Lobo RA, Chang L: The ratio of androstenedione:11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. Fertil Steril 1992; 58: 148-52.
32. Dewailly D, Duhamel A, Robert Y, et al.: Interrelationship between ultrasonography and biology in the diagnosis of polycystic ovarian disease. Ann NY Acad Sci 1993; 687: 206-16.
33. Robert Y, Dubrulle F, Gaillandre G, et al.: Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification. Fertil Steril 1995 (in press).
34. Adams J, Poison DW, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293: 355-9.
35. Kuttenn F, Rigaud C, Wright F, et al.: Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 1980; 51: 1107-11.
36. Franks S: Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989; 1: 87-119.
37. Clayton RN, Ogden V, Hodgkinson J, et al.: How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol 1992; 37: 127-34.
38. Poison DW, Wadsworth J, Adams J, Franks S: Polycystic ovaries: a common finding in normal women. Lancet 1988; 16: 870-2.
39. Sagle M, Bishop K, Beard RW: Recurrent early miscarriage and polycystic ovaries. BMJ 1988; 297: 1027-8.
40. Lambert-Messerlian GM, Hall JE, Sluss PM, et al.: Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1994; 79: 45-50.
41. Van Lock, PFA: Hypothalamic-pituitary-ovarian relationships in the polycystic ovary syndrome. In Functional Morphology of the Human Ovary, edited by Coutts JRT, pp. 167-76, Cambridge, MA, MTP Press Limited 1981.
42. Erickson GF, Magoffin DA, Garzo VG, Cheung AP, Chang RJ: Granulosa cells of polycystic ovaries: are they normal or abnormal? Hum Reprod 1992; 7: 293-9.
43. Kubota T, Kamada S, Ohara M, et al.: 34K-Insulin like growth factor II in follicular fluid of the patients with in vitro fertilization and embryo transfer. Fertil Steril 1993; 59: 844-9.
44. El-Roeiy A, Chen X, Robert VJ, et al.: Expression of the genes encoding the insulin like growth factors (IGFI and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 1994; 78: 1488-96.
45. Pache TD, Hop WCJ, De Jong FH, et al.: 17β-Estradiol, androstenedione and inhibin levls in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. Clin Endocrinol 1992; 36: 565-71.
46. Franks S, Hamilton-Fairley D, Kiddy DS, Mason HD: Growth factors and the polycystic ovary. In Local Regulation of Ovarian Function, edited by Sjöberg NO, Hamberger L, Janson PO, Owman Ch., Coelingh Bennink HJT, pp. 97-106, Pearl River, NY, The Parthenon Publishing Group 1992.
47. Mason HD, Margara R, Winston RML, Beard RW, Reed MJ, Franks S: Inhibition of oestradiol production by epidermal growth factor in human granulosa cells of normal and polycystic ovaries. Clin Endocrinol 1990; 33: 511-7.
48. Garzo VG, Dorrington JH: Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin. Am J Obstet Gynecol 1984; 148: 657-62.
49. Yong EL, Baird DT, Yates R, Reichert E, Hillier SG: Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab 1992; 74: 842-9.
50. Mason HD, Willis DS, Beard RW, Winston RML, Margara R, Franks S: Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79: 1355-60.
51. Adams J, Franks S, Poison DW, et al.: Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985, 2: 1375-8.
52. Futterweit W, Kreiger DT: Pituitary tumours associated with hyperprolactinaemia and polycystic ovarian disease. Fertil Steril 1979; 31: 608-13.
53. Gysler M, March ChM, Mishell DR, Bailey EJ: A decade's experience with an individualized clomiphene treatment regimen including its effects on the post-coital test. Fertil Steril 1982; 37: 161-7.
54. Baird DT, Howles CM: Induction of ovulation with gonadotrophin: HMG versus purified FSH. In Ovulation Induction: Basic Science and Clinical Advances, edited by Filicori M, Flamigni C, pp. 135-43, Amsterdam, Excerpta Medica 1994.
55. Van der Meer M, Hompes PGA, Scheele F, Shoute E, Veersema S, Schoemaker J: Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome. Hum Reprod 1994; 9: 1612-7.
56. Fauser BCJM: Step down follicle stimulating hormone regimens in PCOS. In Ovulation Induction: Basic Science and Clinical Advances, edited by Filicori M, Flamigni C, pp. 153-162, Amsterdam, Excerpta Medica 1994.
57. Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Paterson C, Franks S: Low-dose gonadotrophin therapy for induction of ovulation in 100 women with PCOS. Hum Reprod 1991; 6: 1095-9.
58. Balen AH, Tan SL, Macdougall J, Jacobs HS: Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8: 959-64.
59. Filicori M, Flamigni C, Dellai P, et al.: Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994; 79: 1215-20.
60. Jacobs HS: Pulsatile GnRH in multifollicular and polycystic ovary patients. In Ovulation Induction: Basic Science and Clinical Advances, edited by Filicori M, Flamigni C, pp. 267-76, Amsterdam, Excerpta Medica 1994.
61. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181.
62. Heylen SM, Puttemans PJ, Brosens IA: Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Reprod 1994; 9: 1038-42.
63. Balen AH, Jacobs HS: A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994; 62: 921-5.
64. Bazin B, Thevenot R, Bursaux C, Paris J: Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987; 94: 1199-204.
65. Pasquali R, Casimirri F: The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993; 39: 1-6.
66. Bringer J, Lefebvre P, Boulet F, et al.: Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann NY Acad Sci 1993; 687: 115-23.
67. Pasquali R, Casimirri F, Venturoli D, et al.: Body fat distribution has weight-independent effects on clinical, hormonal and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 6: 706-13.
68. Conway GS, Jacobs HS: Clinical implications of hyperinsulinaemia in women. Clin Endocrinol 1993; 39: 623-32.
69. DunaiF A, Givens J, Haseltine F, Merriam G (editors): The Polycystic Ovary Syndrome. Cambridge, MA, Blackwell Scientific Publications 1992.
70. Dunaif A: Insulin resistance and ovarian hyperandrogenism. Endocrinologist 1992; 2: 248-60.
71. Dahlgren E, Johansson S, Lindstedt G, et al.: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-13.
72. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Poly28 cystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992; 71: 599-604.
73. Conway GS, AgrawaL R, Betteridge DJ, Jacobs HS: Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992; 37: 119-25.
74. McKelgue P: Are women with polycystic ovary syndrome at special risk for coronary heart disease? Clin Endocrinol 1992; 37: 117-8.
75. Stoll, BA, Vatten, LJ, Kvinnsland, S: Does early physical maturity influence breast cancer risk? Acta Oncol 1994; 33: 171-6.
76. O'Meara NM, Blackman JD, Ehrmann DA, et al.: Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1241-7.
77. Plymate SR, Fariss BL, Basset ML, Matej L: Obesity and its role in polycystic ovary syndrome. J Clin Endocrinol Metab 1981, 66: 52: 1246-8.
78. Holte J, Bergh T, Berne C, Lithell H: Serum lipoprotein profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol 1994; 41: 463-72.
79. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
80. Rebuffe-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Bjorntorp P: Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989; 21: 391-7.
81. Nestler JE: Sex hormone binding globulin: a marker for hyperin-sulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993; 76: 1221-4.
82. Sharp PS, Kiddy DS, Reed MJ, Ahyaoku V, Johnston DO, Franks S: Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol 1991; 35: 253-7.
83. Conway GS, Jacobs HS, Holly JMP, Wass JAH: Effects of luteinizing hormone, insulin, insulin-like growth factor-I, and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol 1990; 33: 593-603.
84. Kiddy DS, Halmilton-Fairley D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-11.
85. Velasquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54.
86. Hsueh AJW, Billig H, Tsafriri A: Ovarian follicle atresia: a hormonally controlled apopoptic process. Endocr Rev 1994; 15:707-24.
87. Franks S, White DM: Prevalence of and etiological factors in polycystic ovarian syndrome. Ann NY Acad Sci 1993; 687: 112-4.
88. Hoffman F, Meger C: On the action of intraovarian injection of androgen on follicle and corpus luteum maturation in women. Geburtsh Frauenheilkd 1965; 25: 1132-7.
89. Futterweit W, Deligdisch L: Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986; 62: 16-21.
90. Magoffin DA, Erickson GF: Direct inhibitory effect of estrogen on LH-stimulated androgen synthesis by ovarian cells cultured in defined medium. Mol Cell Endocrinol 1982; 28: 81-9.
91. Rabinovici J, Spencer SJ, Doldi N, Goldsmith PC, Schwall R, Jaffe RB: Activin-A as an intraovarian modulator: actions, localization, and regulation of the intact dimer in human ovarian cells. J Clin Invest 1992; 89: 1528-36.
92. Elkind-Hirsch KE, Valdes CT, Malinak LR: Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril 1993; 60: 634-41.
93. Conway GS, Jacobs HS, Holly JMP, Wass JAH: Effects of luteinizing hormone, insulin, insulin-like growth factor-I, and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol 1990; 33: 593-603.
94. Nestler JE, Powers LP, Matt DW, et al.: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-9.
95. Lanzone A, Fulghesu AM, Guido M, Fortini A, Caruso A, Mancuso S: Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. Fertil Steril 1992; 58: 296-301.
96. Zhou J, Bondy C: Anatomy of the human ovarian insulin-like growth factors. Biol Reprod 1993; 48: 467-82.
97. Poretsky L, Grigorescu F, Seibel M, Moses AC, Fliers JS: Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab 1985; 61: 728-34.
98. Cara JF: Nongonadotrophic regulation of ovarian function: insulin. In Ovulation Induction: Basic Science and Clinical Advances, edited by Filicori M, Flamigni C, pp. 65-72, Amsterdam, Excerpta Medica 1994.
99. Homburg R, Pariente C, Lunenfeld B, Jacobs HS: The role of insulin like growth factor-I (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 1992; 7: 379-1383.
100. Cortet-Rudelli C, Devemy F, Mingaud F, Koistinen R, Seppala M, Dewailly D: Relationship between IGFBP-1 and androgens in the polycystic ovarian disease (PCOD). The Endocrine Society, Anaheim, CA, June 15-18, 1994, Abstract 1774.
101. Franks S, Mason HD: Polycystic ovary syndrome: interaction of follicle stimulating hormone and polypeptide growth factors in estradiol production by human granulosa cells. J Steroid Biochem Mol Biol 1991; 40: 405-9.
102. Eden, JA, Jones, J, Carter, GD, Alabghband-Zadeh: Follicular fluid concentrations of insulin like growth factor 1, epidermal growth factor, transforming growth factor a and sex steroids in volume matched normal and polycystic human follicles. J Clin Endocrinol Metab 1990; 32: 395-405.
103. Giudice LC: Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992; 13: 641.
104. Willis D, Gilling-Smith C, Mason H, Franks S: Insulin (INS) and LH interactions in human granulosa cells (GC). The Endocrine Society, Anaheim, CA, June 15-18, 1994, Abstract 463.
105. Venturoli S, Porcu E, Fabbri R, et al.: Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities. Fertil Steril 1987; 48: 78-85.